Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME

February 20, 2024 8:05 AM EST

PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).

... More